Compare Synthaverse SA with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 6.11%
- The company has been able to generate a Return on Equity (avg) of 6.11% signifying low profitability per unit of shareholders funds
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
Poor long term growth as Net Sales has grown by an annual rate of 5.68% over the last 5 years
4
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
PLN 285 Million (Small Cap)
247.00
NA
0.00%
0.64
-4.64%
2.18
Revenue and Profits:
Net Sales:
5 Million
(Quarterly Results - Sep 2025)
Net Profit:
-8 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.32%
0%
-8.32%
6 Months
-25.1%
0%
-25.1%
1 Year
-24.87%
0%
-24.87%
2 Years
-5.67%
0%
-5.67%
3 Years
-38.38%
0%
-38.38%
4 Years
-10.62%
0%
-10.62%
5 Years
-56.04%
0%
-56.04%
Synthaverse SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.68%
EBIT Growth (5y)
-191.13%
EBIT to Interest (avg)
5.05
Debt to EBITDA (avg)
1.90
Net Debt to Equity (avg)
0.70
Sales to Capital Employed (avg)
0.33
Tax Ratio
26.69%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.25%
ROE (avg)
6.11%
Valuation key factors
Factor
Value
P/E Ratio
247
Industry P/E
Price to Book Value
2.60
EV to EBIT
114.73
EV to EBITDA
25.59
EV to Capital Employed
1.92
EV to Sales
6.22
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1.67%
ROE (Latest)
1.05%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
4.80
13.40
-64.18%
Operating Profit (PBDIT) excl Other Income
-3.50
2.10
-266.67%
Interest
0.90
0.90
Exceptional Items
0.00
0.00
Consolidate Net Profit
-7.70
-0.40
-1,825.00%
Operating Profit Margin (Excl OI)
-1,395.20%
-29.50%
-136.57%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is -64.18% vs 65.43% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is -1,825.00% vs 83.33% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
71.80
58.60
22.53%
Operating Profit (PBDIT) excl Other Income
20.00
15.80
26.58%
Interest
2.50
0.90
177.78%
Exceptional Items
0.00
0.00
Consolidate Net Profit
7.60
4.80
58.33%
Operating Profit Margin (Excl OI)
166.60%
156.90%
0.97%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 22.53% vs 16.27% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 58.33% vs -21.31% in Dec 2023
About Synthaverse SA 
Synthaverse SA
Pharmaceuticals & Biotechnology
Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Poland-based company engaged in the pharmaceuticals industry.
Company Coordinates 
Company Details
Ul. Uniwersytecka 10 , LUBLIN None : 20-029
Registrar Details






